Belatacept
| Clinical data | |
|---|---|
| Trade names | Nulojix |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a606016 |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[2] which is a molecule crucial in the regulation of T-cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.
Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.
{{cite press release}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |